Dose Regimen Study of SLI-F06 in Healthy Volunteers

A Randomized, Within Subject Controlled, Dose Regimen Study of SLI-F06 in Healthy Volunteers for Improvement in Scar Appearance

Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance

Study Overview

• Status: Recruiting
• Conditions: Scar; Wound Healing
• Intervention / Treatment: Drug: SLI-F06

Detailed Description

The is a Phase IIa dose-regimen study of small punch biopsy scars created on the upper and lower back of healthy patients. All excisions will be randomized to treatment with vehicle or 4 doses of SLI-F06 drug product. Patients will be divided into 3 cohorts, with Cohort B receiving the same doses as Cohort A but daily for a total of 5 days. Cohort C will receive up to twice the concentration of Cohort A potentially divided into 2 doses, with both cohorts treated only on treatment Day 0. Scars will be assessed for improvement by both the investigator and the patient at follow-up visits over 6-9 months.

Duration of study-approximately 7-10 months.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Elisabeth J Leeflang, MD; Phone Number: 213-788-2128; Email: ELeeflang@scarlesslabs.com

Study Locations

• United States
  • California
    • Encinitas, California, United States, 92024
      • Recruiting
      • California Dermatology & Clinical Research Institute
      • Contact: Tiffany Robb; Phone Number: 760-203-3839; Email: trobb@cdcrinstitute.com
      • Principal Investigator: Stacy Smith, MD
  • Texas
    • Austin, Texas, United States, 78759
      • Recruiting
      • DermResearch
      • Principal Investigator: Janet Dubois, MD
      • Contact: Jewel Medley; Phone Number: 512-349-9889; Email: jewel@vial.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy subjects, male or female, ages 18 to 65
2. Subjects with a Body Mass Index (BMI) 18.5-30 and at least 40 kg
3. Subjects with symmetrically located right and left scapular lines relative to the midline, and at least 12 cm distance between the right and left scapular lines.
4. Be able to follow study instructions and likely to complete all required visits.
5. Sign the Institutional Review Board (IRB)-approved informed consent form (ICF, which includes the Photographic and Video Release Form) prior to any study-related procedures being performed.

Exclusion Criteria:

1. Female subjects who are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control methods
2. Subjects who were previously treated with SLI-F06
3. Subjects with evidence of hypertrophic or keloid scarring
4. Subjects with obvious back abnormalities (e.g., severe scoliosis)
5. Subjects with tattoos or previous scars in the study areas

6. Subjects who are poor surgical candidates

   1. Active disease that could interfere with or limit wound healing (e.g., diabetes, anemia, renal disease, hepatic disease, cardiac disease, or immune system disorders)
   2. History of clinically significant bleeding disorder or coagulation disorders
   3. Use of any tobacco/inhaled nicotine products including vaping within 12 months.
7. Subjects with evidence of skin infection or rash on the back
8. Subjects with history of active or uncontrolled skin disease (e.g., psoriasis, eczema, rosacea, vitiligo, skin cancer) that could interfere with the study or interpretation of the study outcomes
9. Subjects with a history of clinically significant allergies, especially drug hypersensitivity to lignocaine or allergy to adhesive surgical dressings
10. Subjects with any clinically significant abnormality following review of pre-study laboratory data and full physical examination

11. Subjects who are taking or have taken known anticoagulants:

    1. Blood thinners (e.g., coumadin, rivaroxaban, apixaban) within 2 months prior to day 0
    2. Others such as aspirin or aspirin containing products, Non-steroidal anti-inflammatory drugs (NSAIDs), vitamin E, fish oil within 14 days prior to day 0.
12. Subjects taking systemic or topical steroids within 4 weeks of Day 0
13. Subjects with excessive alcohol use, defined as >28 units of alcohol per week (1unit = 8 g alcohol, 1shot spirits, half- pint beer, or 5 oz wine)
14. Subjects who have evidence of drug abuse
15. Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen per medical history
16. Subjects with a history of poor or delayed wound healing (e.g., prior wound dehiscence, chronic wound, leg ulcer)
17. Subjects treated with an investigational drug or device within 30 days prior to day 0
18. Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, or may significantly interfere with the subject's participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A; Injection of SLI-F06 on Treatment Day 0, immediately after wound closure: Formulation buffer (control); 3.75 mg SLI-F06 total dose per wound (1X); 7.5 mg SLI-F06 total dose per wound (2X); 15 mg SLI-F06 total dose per wound (4X)	Drug: SLI-F06; Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
Experimental: Cohort B; Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and on Days 1, 2, 3, 4: Formulation buffer (control); 3.75 mg SLI-F06 total dose per wound (1X); 7.5 mg SLI-F06 total dose per wound (2X); 15 mg SLI-F06 total dose per wound (4X)	Drug: SLI-F06; Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
Experimental: Cohort C; Injection of SLI-F06 on Treatment Day 0, immediately after wound closure and then 3 hours after for wounds dosed twice: Formulation buffer (control) once; 7.5 mg SLI-F06 total dose per wound (2X) once; 3.75 mg SLI-F06 dose per wound (1X) twice, total dose 7.5 mg; 7.5 mg SLI-F06 total dose per wound (2X), total dose 15 mg	Drug: SLI-F06; Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Scarless Labs Observer Scale	Exploratory scale for observer to assess different scar parameters, including Surface Area, Elevation / Depression, Relief, Thickness, Pliability, Vascularity and Pigmentation. The observer then makes an Overall global assessment (scale 0 to -3) of the scar based on the clinical assessment of the scar parameters. All parameters are assessed on a scale of 0-3 (except pigmentation, -3 [hypo] to +3 [hyper]), where 0 correlates to a scar that is indistinguishable from normal skin with greater deviation from 0 correlating with more severe scar. The observer creates a forced rank between scars on the upper and lower back based on best (1) to worst (4) cosmetically.	Months 1,3,6 and possibly 9

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient and Observer Scar Assessment Scale (POSAS) Observer Scale	Established scar scale with observer rating of 1 (normal skin) to 10 (worst scar imaginable) for 6 different parameters (vascularity, pigmentation, thickness, relief, pliability, surface area) and overall opinion rated on the same 1-10 scale. The sum of these scores is added for a total value with a higher number being worse.	Months 1,3,6 and possibly 9
Scarless Labs Patient Scale	Exploratory scale for subjects to assess different scar parameters, with 0 being no difference in pain or itching of the scar compared with normal skin and -3 being severe or worse. Patients then select a face on a modified Wong-Baker scale for their overall opinion of the scar.	Months 1,3,6 and possibly 9

Collaborators and Investigators

• Sponsor: Scarless Laboratories, Inc.
• Investigators: Study Director: Elisabeth J Leeflang, MD, Scarless Laboratories, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 25, 2022
• Primary Completion (Estimated): July 25, 2024
• Study Completion (Estimated): October 25, 2024

Study Registration Dates

• First Submitted: August 11, 2022
• First Submitted That Met QC Criteria: August 11, 2022
• First Posted (Actual): August 15, 2022

Study Record Updates

• Last Update Posted (Actual): July 27, 2023
• Last Update Submitted That Met QC Criteria: July 24, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Wound Healing; Scar; Scar Appearance
• Other Study ID Numbers: SLI-F06-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No